
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is leveraging its Nucleosomics platform to develop cost-effective diagnostic blood tests, with a focus on various diseases, including cancers and conditions linked to NETosis. The company's successful validation of the Nu.Q Lung Cancer Test is anticipated to attract strategic partnerships with major diagnostic and pharmaceutical players, which could significantly de-risk its technology and enhance its market presence. Furthermore, with the introduction of the Nu.Q Vet Cancer Test in over 1,000 Japanese veterinary hospitals, supported by a partnership with Fujifilm Vet Systems, VolitionRX is well-positioned to expand its market reach and drive revenue growth through increased adoption of its innovative diagnostic tools in both human and animal health sectors.
Bears say
VolitionRX Ltd is working on a study aimed at reducing the high false-positive rates in low-dose computed tomography (LDCT) screenings for pulmonary nodules, a challenge that may hinder its diagnostic capabilities and market acceptance. Despite its innovative Nucleosomics platform aimed at developing cost-effective blood tests for various diseases, the company's focus on addressing complex diagnostic issues could delay revenue generation and market penetration. Additionally, the potential for unnecessary invasive procedures stemming from current screening methods raises concerns about the company's ability to create a competitive advantage in a challenging healthcare landscape.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares